Latest News
Late-Breaking HOPA News: Redefining Relapse: What MajesTEC-3 Means for the Treatment of Multiple Myeloma
Sanja Zepcan, PharmD, BCPS, BCOP, and Emily Rux, PharmD, BCOP, discuss the clinical questions raised by the recent MajesTEC-3 trial and the potential changes it finds in the treatment of multiple myeloma.
Pharmacist's Application to Practice: Pirtobrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Cristina V. Martinez, PharmD, PGY2 Oncology Pharmacy Resident, and Hunter Sowell, PharmD, BCOP, Clinical Pharmacy Specialist Oncology, analyze the potential role for pirtobrutinib in treating chronic lymphocytic leukemia and small lymphocytic lymphoma.
Pharmacy Students and Oncology Pharmacists Combat Cancer Misinformation with National Initiative
The Hematology/Oncology Pharmacy Association (HOPA) is proud to team up with the Student National Pharmaceutical Association (SNPhA) for the Cancer Clarity Challenge, a new national competition.
Pharmacist's Application to Practice: Taletrectinib
Benjamin Pastore, PharmD, PGY2 Adult Oncology Pharmacy Resident, and Jasmine Patel, PharmD, BCOP, Clinical Pharmacy Specialist - Thoracic Oncology, discuss the potential role of taletrectinib in the treatment of metastatic non-small cell lung cancer.
Pharmacist's Application to Practice: Zongertinib
Reyam Katchi, PharmD, PGY2 Hematology/Oncology Pharmacy Resident, and Kiera Roubal, PharmD, Oncology Clinical Pharmacist, break down the potential role for zongertinib in the treatment of non-squamous NSCLC with HER2 TKD activating mutations.
Explore more from HOPA
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
The data from this trial confirm that FTD–TPI plus bevacizumab is an effective treatment option for patients with refractory metastatic colorectal cancer, irrespective of mutational status, which side the tumor is on, and whether patients have previously
